NCT00836654View on ClinicalTrials.gov

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)Malignant Ascites
Interventions
BIOLOGICAL

Catumaxomab (Removab)

Puncture free survival

PROCEDURE

paracentesis

Sponsors

Lead Sponsor

Neovii Biotech
All Listed Sponsors
lead

Neovii Biotech

INDUSTRY

NCT00836654 - Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group | Biotech Hunter | Biotech Hunter